US · ELDN
Eledon Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Irvine, CA 92612
- Website
- eledon.com
Price · as of 2024-12-31
$3.69
Market cap 157.07M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $2,217.78 | ||||
| 2015 | $965.52 | ||||
| 2016 | $134.62 | ||||
| 2017 | $70.38 | ||||
| 2018 | $79.20 | ||||
| 2019 | $8.71 | ||||
| 2020 | $13.81 | ||||
| 2021 | $3.40 | ||||
| 2022 | $2.16 | ||||
| 2023 | $1.67 | ||||
| 2024 | $3.79 |
AI valuation
Our deep-learning model estimates Eledon Pharmaceuticals, Inc.'s (ELDN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $3.69
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ELDN | Eledon Pharmaceuticals, I… | $3.69 | 157.07M | — | — | — | — | -5.08 | 1.56 | — | -1.26 | — | 2.15 | 0.00% | — | — | -57.73% | 218.52% | -27.16% | 0.01 | — | 12.42 | 12.11 | 0.55 | -5427.00% | — | 1959.00% | -25.69% | -4.08 | 146.36% | 0.00% | 0.00% | 8.35% | -0.63 | -0.95 | — | -1.36 |
| ABEO | Abeona Therapeutics Inc. | $5.12 | 277.46M | +447% | — | — | — | -3.32 | 4.81 | — | -2.42 | — | 4.81 | 0.00% | — | — | -216.57% | 205.01% | -73.71% | 0.52 | -15.26 | 6.08 | 5.99 | 0.01 | -3874.00% | -10000.00% | 5656.00% | -27.60% | -3.38 | 186.65% | 0.00% | 0.00% | 0.00% | -2.14 | -2.35 | — | -9.51 |
| ACHV | Achieve Life Sciences, In… | $4.56 | 242.75M | — | — | — | — | -2.53 | 4.82 | — | -2.04 | — | 5.33 | 0.00% | — | — | -409.51% | 2085.90% | -137.33% | 0.48 | -17.92 | 5.46 | 5.14 | 0.07 | -1733.00% | — | 2151.00% | -29.56% | -4.46 | 1589.43% | 0.00% | 0.00% | 3.93% | -1.95 | -2.56 | — | -6.45 |
| ALLO | Allogene Therapeutics, In… | $2.78 | 624.75M | +924% | -60% | — | +3,007% | -1.65 | 1.01 | 19304.10 | -0.92 | — | 1.01 | 100.00% | -1241813.64% | -1170863.64% | -55.13% | -144.12% | -43.24% | 0.21 | -1509.39 | 8.54 | 8.29 | -0.06 | -3684.00% | -7684.00% | -1599.00% | -47.33% | -5.64 | -106.03% | 0.00% | 0.00% | 0.00% | -0.82 | -1.11 | 10135.01 | -3.69 |
| AVIR | Atea Pharmaceuticals, Inc… | $4.68 | 365.63M | — | — | — | — | -1.50 | 0.57 | — | 1.53 | -6.59 | 0.57 | 0.00% | — | — | -33.88% | 1111.34% | -31.78% | 0.00 | — | 24.85 | 24.44 | 0.48 | 2270.00% | — | 5867.00% | -53.78% | -7.28 | 780.43% | 0.00% | 0.00% | 0.00% | 1.04 | 1.48 | — | 4.54 |
| EDIT | Editas Medicine, Inc. | $2.20 | 214.76M | +883% | +13% | — | +6,172% | -0.60 | 1.05 | 4.38 | 0.40 | -1.40 | 1.05 | 100.00% | -777.22% | -733.72% | -98.10% | 1925.86% | -56.40% | 0.26 | — | 3.75 | 3.71 | 0.41 | 4257.00% | -5864.00% | 6005.00% | -154.71% | -2.72 | 1680.16% | 0.00% | 0.00% | 15.11% | 0.37 | 0.43 | -2.89 | -7.20 |
| HUMA | Humacyte, Inc. | $1.12 | 159.24M | — | — | — | — | -2.46 | -6.95 | — | -2.55 | -13.86 | -6.95 | 0.00% | — | — | 760.17% | 252.76% | -111.77% | -0.31 | -12.33 | 2.40 | 2.25 | 0.21 | 1776.00% | — | 3190.00% | -27.23% | -4.92 | 220.27% | 0.00% | 0.00% | 1.48% | -2.95 | -3.39 | — | -8.31 |
| PBYI | Puma Biotechnology, Inc. | $5.70 | 287.23M | +433% | +114% | 0% | -22% | 10.32 | 2.46 | 1.41 | 4.73 | — | 3.61 | 74.53% | 16.33% | 13.62% | 27.97% | 51.23% | 14.48% | 0.22 | 5.63 | 2.00 | 1.86 | -0.02 | -161.00% | -91.00% | 738.00% | 13.00% | 0.51 | 65.93% | 0.00% | 0.00% | 1.85% | 6.76 | 6.04 | 1.10 | -3.99 |
| TRDA | Entrada Therapeutics, Inc… | $11.93 | 455.96M | +114% | -46% | — | +2,115% | -3.36 | 1.58 | 19.01 | -1.67 | — | 1.58 | 83.89% | -621.13% | -565.48% | -39.13% | -244.32% | -31.81% | 0.17 | — | 12.53 | 12.09 | 0.28 | -30655.00% | -8794.00% | 18973.00% | -26.81% | -5.26 | -200.46% | 0.00% | 0.00% | 0.10% | -1.51 | -1.84 | 9.38 | 2.64 |
| VNDA | Vanda Pharmaceuticals Inc… | $8.91 | 526.65M | +158% | -50% | — | — | -2.18 | 1.47 | 2.23 | -1.65 | -0.20 | 2.29 | 93.96% | -69.95% | -102.02% | -50.93% | -119.87% | -38.51% | 0.04 | — | 2.39 | 2.19 | 0.52 | 106875.00% | 872.00% | 57976.00% | -22.94% | -0.75 | -87.57% | 0.00% | 0.00% | 0.00% | -1.52 | -2.08 | 1.07 | 0.57 |
| VYGR | Voyager Therapeutics, Inc… | $4.10 | 227.96M | +883% | -19% | — | +1,465% | -3.78 | 0.82 | 3.07 | -0.29 | — | 0.82 | 100.00% | -104.11% | -81.25% | -24.25% | -162.45% | -17.47% | 0.15 | — | 5.56 | 5.45 | 0.35 | -13805.00% | -6800.00% | -12522.00% | -7.67% | -0.31 | -36.73% | 0.00% | 0.00% | 0.00% | -0.27 | -1.21 | 0.28 | 0.62 |
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
- CEO
- David-Alexandre C. Gros
- Employees
- 31
- Beta
- 0.89
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $3.69) − 1 = — (DCF, example).